Background: Patients with prognosis recurrent/metastatic (R/M) salivary gland carcinomas (SGCs) are poor. Activity of axitinib was demonstrated in adenoid cystic carcinoma (ACC). We tested axitinib in a larger cohort of R/M SGCs including non-ACC. Methods: Axitinib was administered at 10 mg daily (dose escalation allowed) until progression or unacceptable toxicity. Null hypothesis would be rejected if more than 3 of 26 responses were observed. Results: Twenty-six patients (50% were male; 6 ACC, 20 non-ACC) were treated. Response rate was 8% (2 partial responses), 13 stable disease (>6 months in 7 patients) and 11 disease progression. Median progression-free survival and overall survival were 5.5 and 26.2 months, respectively. All patients had at least one adverse event: stomatitis (69%), fatigue (58%) and hypertension (54%) were the most frequent. Conclusions: This trial did not meet its primary endpoint hence axitinib should not be considered for further investigations in SGCs. Safety profile was in line with the scientific literature.

Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract / L.D. Locati, S. Cavalieri, C. Bergamini, C. Resteghini, S. Alfieri, G. Calareso, P. Bossi, F. Perrone, E. Tamborini, P. Quattrone, R. Granata, D. Galbiati, F. Platini, E. Orlandi, L. Mariani, L. Licitra. - In: HEAD & NECK. - ISSN 1043-3074. - 41:10(2019 Oct), pp. 3670-3676. [10.1002/hed.25891]

Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract

S. Cavalieri;C. Resteghini;R. Granata;D. Galbiati;F. Platini;L. Mariani;L. Licitra
2019

Abstract

Background: Patients with prognosis recurrent/metastatic (R/M) salivary gland carcinomas (SGCs) are poor. Activity of axitinib was demonstrated in adenoid cystic carcinoma (ACC). We tested axitinib in a larger cohort of R/M SGCs including non-ACC. Methods: Axitinib was administered at 10 mg daily (dose escalation allowed) until progression or unacceptable toxicity. Null hypothesis would be rejected if more than 3 of 26 responses were observed. Results: Twenty-six patients (50% were male; 6 ACC, 20 non-ACC) were treated. Response rate was 8% (2 partial responses), 13 stable disease (>6 months in 7 patients) and 11 disease progression. Median progression-free survival and overall survival were 5.5 and 26.2 months, respectively. All patients had at least one adverse event: stomatitis (69%), fatigue (58%) and hypertension (54%) were the most frequent. Conclusions: This trial did not meet its primary endpoint hence axitinib should not be considered for further investigations in SGCs. Safety profile was in line with the scientific literature.
adenoid cystic carcinoma; antiangiogenetic; axitinib; salivary gland cancer; tyrosine kinase inhibitor
Settore MED/06 - Oncologia Medica
ott-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
6 - PMID 31355973.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 717.57 kB
Formato Adobe PDF
717.57 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Locati_et_al-2019-Head_&_Neck.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 734.07 kB
Formato Adobe PDF
734.07 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/678820
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 32
social impact